Clinical Trial Update: The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED) [Phase 2]

View source ↗

Summary

This document notes the completion of a Phase 2 trial evaluating MK-0633 in patients with atherosclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• MK-0633 (MK-0633)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Atherosclerosis | Phase 2 | Status: COMPLETED